SARS-CoV-2 in human milk is inactivated by Holder pasteurization but not cold storage

INTRODUCTION

As the COVID-19 pandemic evolves, human milk banks worldwide continue to provide donor human milk to vulnerable infants who lack access to mother’s own milk.¹ Under these circumstances, ensuring the safety of donor human milk is paramount, as the risk of vertical transmission of SARS-CoV-2 is not well understood.² Although case series have reported that SARS-CoV-2 was not detected in breast milk,³ there have been recent case reports^4,5 of SARS-CoV-2 detected in breast milk from women with symptomatic COVID-19 infection. Expressed milk may theoretically become contaminated from maternal respiratory secretions or via skin, though no evidence suggests that breast milk is a means of transmission of SARS-CoV-2 to infants. Consistent with available data, international guidelines recommend mothers with COVID-19 continue to provide breast milk for their babies as the benefits outweigh risks of virus transmission.² Although low, the potential risk of SARS-CoV-2 transmission through milk is concerning for milk banks globally.¹ Here, we investigate the inactivation of SARS-CoV-2 in human milk by pasteurisation, and the stability of SARS-CoV-2 in human milk under cold storage (freezing or refrigeration).

METHODS

Frozen (14 weeks) and freshly expressed (<12 hours) human milk was obtained from healthy donors to Australian Red Cross Lifeblood Milk.

For the assessment of viral inactivation by pasteurisation, SARS-CoV-2 10⁵ TCID50/mL was diluted 1:10 in previously frozen human milk or non-supplemented Minimum Essential Medium (MEM, Gibco™, Life Technologies, CA) (control). Triplicates of each sample were layered onto uninfected cells after being subjected to Holder pasteurisation (63°C for 30 minutes), under-pasteurisation (56°C for 30 minutes) or were unpasteurised. Endpoint titration of samples was performed on Vero cells in sextuplicate, and the 50% tissue culture infectious dose (TCID50) determined at 72 hours post-infection using standard methods.⁶

Freshly expressed milk from two donors and MEM (control) was similarly inoculated with SARS-CoV-2 to assess virus stability under cold storage conditions. Infectious titres of samples were measured at the time of inoculation, and after 48 hours of storage at 4°C or -30°C. This project was approved by the Australian Red Cross Lifeblood HREC (Clifford 27042020).

RESULTS

Following heating to 63°C or 56°C for 30 minutes, SARS-CoV-2 replication competent (i.e. live) virus was undetected in both milk and MEM (Fig. 1A). After 48 hours there was no reduction in SARS-CoV-2 infectious titre in milk samples kept at 4°C, and a 0.41 log-unit reduction in samples frozen at -30°C (Fig. 1B). In the control media (MEM), there was a 0.02 and 0.25 log-unit reduction in infectious titres of samples stored at 4°C and -30°C respectively. Whilst freezing of milk and MEM samples resulted in a slight reduction in infectious titre, viable virus was still recovered after 48 hours of storage.

• Download figure
• Open in new tab

Figure 1.

Viability of SARS-CoV-2 in breast milk. (A) Inactivation by pasteurisation. Previously frozen human breast milk or MEM was inoculated with SARS-CoV-2. Infectious titres were determined in triplicates of each sample that were subjected to Holder (63°C) pasteurisation (N.D.), under-pasteurisation (56°C) (N.D), or were unpasteurised (black). (B) Stability under cold storage conditions. Freshly expressed breast milk (n=2) or MEM (n=3) was inoculated with SARS-CoV-2. Infectious titres of samples were determined at 0 hours post-inoculation (black), and after 48 hours of storage at either +4°C (grey) or -30°C (blue). Infectious titres for all experiments were determined using endpoint titration on Vero cells in sextuplicate. Error bars indicate the standard error of the mean. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; MEM, Minimum Essential Medium; N.D., not detected; TCID50, 50% tissue culture infectious dose.

DISCUSSION

Milk banks employ many risk mitigation strategies to ensure the safety of donor milk, with donor selection criteria, serological and/or viral nucleic acid screening, validated frozen transport methods, microbial testing, and pasteurisation.⁷ For SARS-CoV-2, this includes specific questions to screen for symptoms of COVID-19, deferral of donors with COVID-19 or close contact with COVID-19, and pasteurisation of donor milk. Holder pasteurisation (62.5°C for 30 minutes) is the most common pasteurisation method among milk banks worldwide, and has been shown to inactivate most enveloped viruses, including MERS-CoV⁸ and SARS-CoV-1.⁹ Our findings are consistent with a recent study that reported SARS-CoV-2 is inactivated by heat treatment,¹⁰ although inactivation under Holder pasteurisation has not yet been investigated in human milk. Our findings demonstrate that SARS-CoV-2 can be effectively inactivated by Holder pasteurisation, and confirm that existing milk bank processes will effectively mitigate the risk of transmission of SARS-COV-2 to vulnerable infants through pasteurised donor human milk.

This is the first study to assess the stability of SARS-CoV-2 in human milk. We show that cold storage of SARS-CoV-2 in human milk (either by refrigeration or freezing) does not significantly impact infectious viral load over a 48 hour period. Results of the refrigerated samples are consistent with a recent study not involving human milk that found SARS-CoV-2 to be highly stable at 4 ° C in the environment.¹⁰ Whilst it is yet to be determined whether SARS-CoV-2 detected in breast milk is infectious, these findings may assist in the development of guidelines around expressing and storing milk from COVID-19 infected mothers.